CDKN2B-AS1 and acute myeloid leukemia: The overexpression of ANRIL is associated with poor prognosis and a lower overall survival in GC, LC, HCC, HNSCC/LSCC, RC, iCCA, EC, AML, OS, CC and OC (Table 1).